Skip to main content

Advertisement

Table 8 Nitric oxide scavenging activity of eugenol derivatives

From: Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study

Compound/sample IC50 (µg/mL)a Sr. no IC50 (µg/mL)a
5a 7.156 ± 0.002 13a 20.23 ± 0.073
5b 6.456 ± 0.023 13b 11.74 ± 0.523
7 9.142 ± 0.061 13c 14.63 ± 0.412
9a 9.007 ± 0.014 13d 11.23 ± 0.032
9b 8.095 ± 0.018 16 18.63 ± 0.654
11 10.71 ± 0.743 17 25.61 ± 0.076
Eugenol 11.724 ± 0.003 l-Ascorbic acid 7.523 ± 0.005
  1. aValue are expressed as mean ± SEM, n = 3